Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Di | EXACT Therapeutics AS: Share capital increase registered | - | Oslo Børs | ||
19.12. | EXACT Therapeutics AS: Primary insider notification | - | Oslo Børs | ||
19.12. | EXACT Therapeutics AS: EXACT Therapeutics Expands its Board of Directors following the EGM | 2 | Oslo Børs | ||
18.12. | EXACT Therapeutics AS: Cancellation of subsequent offering | 2 | Oslo Børs | ||
EXACT THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
17.12. | EXACT Therapeutics AS: Minutes from the extraordinary general meeting | 1 | Oslo Børs | ||
11.12. | EXACT Therapeutics AS: Primary insider notification | - | Oslo Børs | ||
11.12. | EXACT Therapeutics AS: Share capital increase registered | - | Oslo Børs | ||
03.12. | EXACT Therapeutics AS: Notice of extraordinary general meeting | 1 | Oslo Børs | ||
03.12. | EXACT Therapeutics AS: EXACT Therapeutics to host virtual company presentation on December 4, 2024 following the announcement of completion of private placement | 1 | Oslo Børs | ||
02.12. | EXACT Therapeutics AS: Contemplated Private Placement | - | Oslo Børs | ||
02.12. | EXACT Therapeutics AS: EXACT Therapeutics Receives Investment from GE HealthCare to Advance Therapeutic Ultrasound in Pancreatic Cancer using ACT® | 10 | Oslo Børs | ||
08.10. | EXACT Therapeutics AS: EXACT Therapeutics initiates preclinical immunotherapy collaboration with Agenus Inc. | 10 | Oslo Børs | ||
02.10. | EXACT Therapeutics AS: EXACT Therapeutics to Present at the bi-annual Contrast Media Research Symposium 2024 | - | Oslo Børs | ||
30.09. | EXACT Therapeutics AS: EXACT Therapeutics announces first half 2024 interim results | 3 | Oslo Børs | ||
25.09. | EXACT Therapeutics AS: EXACT Therapeutics announces grant of immunotherapy patent | 1 | Oslo Børs | ||
13.09. | EXACT Therapeutics AS: Financial calendar | 2 | Oslo Børs | ||
06.08. | EXACT Therapeutics AS: EXACT Therapeutics Company update: Full focus on Phase 2 pancreatic cancer trial | - | Oslo Børs |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
CG ONCOLOGY | 30,040 | +3,19 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates | - Final positive safety and efficacy findings from CORE-001 study of Cretostimogene Grenadenorepvec in combination with Pembrolizumab in BCG-Unresponsive NMIBC simultaneously published online by Nature... ► Artikel lesen | |
QUANTUM-SI | 3,575 | +66,28 % | Pre-market Movers: Intrusion, SES AI, Solid Power, Quantum-Si, Rail Vision | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.55 A.M. ET).In the Green Intrusion Inc. (INTZ) is up over 380% at $2.16.
SES... ► Artikel lesen | |
QIAGEN | 43,310 | +0,69 % | Biotech Report: Qiagen und Evotec leichter | (shareribs.com) Frankfurt / New York 20.12.2024 - Zum Ende der letzten Handelswoche des Jahres stehen die Biotechwerte unter Druck. Im deutschen Handel geht es für Evotec und Qiagen abwärts.Der DAX... ► Artikel lesen | |
TEMPUS AI | 35,120 | -0,48 % | Cathie Woods ARK kauft AMD und TEMPUS AI, verkauft ARCHER AVIATION | ||
RECURSION PHARMACEUTICALS | 7,390 | -3,52 % | Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug... ► Artikel lesen | |
NUVALENT | 80,30 | -2,14 % | Nuvalent-Direktor Shair verkauft Aktien im Wert von 167.565 US-Dollar | ||
EVOTEC | 8,535 | +1,49 % | INDEX-MONITOR: Evotec und Auto1 im MDax - Befesa und Stabilus raus | ZUG (dpa-AFX) - Der Pharma-Wirkstoffforscher Evotec und der Online-Autohändler Auto1 kehren in den Index der mittelgroßen Börsenwerte, den MDax, zurück. Im Gegenzug steigen der Industrie-Recycler Befesa... ► Artikel lesen | |
TARSUS PHARMACEUTICALS | 55,00 | +1,20 % | How Tarsus Pharmaceuticals' Unique Inspiration Is Driving A Triple-Digit Run | ||
DYNE THERAPEUTICS | 23,720 | -3,06 % | Dyne Therapeutics Reports Positive Data From Phase 1/2 DELIVER Trial Of DYNE-251 In DMD | WASHINGTON (dpa-AFX) - Tuesday, Dyne Therapeutics, Inc. (DYN) revealed new clinical findings from its Phase 1/2 DELIVER trial of DYNE-251 for patients with Duchenne muscular dystrophy also known... ► Artikel lesen | |
BIONTECH | 109,40 | -0,18 % | Biontech und Pfizer zahlen für Vergleich in USA | MAINZ (dpa-AFX) - Der Impfstoffhersteller Biontech hat in den USA im Streit um Lizenzgebühren millionenschwere Vergleiche geschlossen. Insgesamt umgerechnet 1,2 Milliarden Euro werden das Unternehmen... ► Artikel lesen | |
ARS PHARMACEUTICALS | 10,790 | -3,23 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates | Commercial launch of neffy® (epinephrine nasal spray) underway in the United StatesSupplemental NDA for neffy®1mg dose granted priority review by FDA; PDUFA target date set for March 6, 2025Exclusive... ► Artikel lesen | |
CELCUITY | 13,840 | +5,81 % | Celcuity (NASDAQ:CELC) Trading Up 3.8% - Here's Why | ||
CANDEL THERAPEUTICS | 8,870 | -3,27 % | Pre-market Movers: Loop Industries, Repare Therapeutics, Candel Therapeutics, Inovio Pharmaceuticals, iSpecimen | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.35 A.M. ET).In the Green Loop Industries, Inc. (LOOP) is up over 56% at $1.93.
iSpecimen... ► Artikel lesen | |
HUMACYTE | 5,500 | +3,97 % | Humacyte (NASDAQ:HUMA) Shares Up 6% - Here's What Happened | ||
RELAY THERAPEUTICS | 4,360 | -2,02 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival | New interim data show 11.4-month median PFS in 2L patients with PI3Ka-mutated, HR+/HER2- metastatic breast cancer at RP2D 39% confirmed ORR across all patients & 67% in patients with kinase mutations... ► Artikel lesen |